Skip to content
Companies

Instylla

Hydrogel liquid embolic that cuts blood flow to tumors

Raised to date

$34.8M

of $35M offered across 1 Form D filing

Still open
$250K
Investors
29
Last filed
Jul 28, 2026

About

Instylla is a Bedford, Massachusetts medical device company founded in 2017 that develops novel resorbable liquid embolic agents for interventional radiology. Its lead product, the Embrace Hydrogel Embolic System, has received FDA premarket approval for hypervascular tumor embolization. The company's initial clinical focus is interventional oncology, with additional work on peripheral vascular embolization and hemostasis. It is privately held and venture-backed.

A hydrogel-based liquid embolic that delivers controlled, targeted and persistent embolization while being resorbable, rather than relying on permanent particle or coil embolics.

Funding

  • EquityFiled Jul 28, 2026Form D/A
    $34.8M/ $35M

Product

Embrace Hydrogel Embolic System

Medical device

An FDA-approved hydrogel liquid embolic system used by interventional radiologists to occlude blood flow to hypervascular tumors.

  • FDA premarket approval for hypervascular tumor embolization
  • Hydrogel liquid embolic chemistry
  • Controlled and targeted vessel occlusion

Built for

Interventional radiologists and interventional oncologists in hospitals and clinical settings

People on file